EUVIMEDEUVIMED entdecken
Crossref

Treatment Patterns and Prognostic Factors of Anti-HER2 Therapy in HER2-positive Advanced/Recurrent Gastric Cancer

Noriko Wada, Yukinori Kurokawa, Tsuyoshi Takahashi, Takuro Saito, Takaomi Hagi, Shigeto Nakai, Kota Momose, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Hidetoshi Eguchi, Yuichiro Doki und 1 weitere

Anticancer Research · 2026

DOI: 10.21873/anticanres.18001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Noriko Wada und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Trastuzumab, Neoplasm Recurrence, Local.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Human epidermal growth factor receptor 2 (HER2) over-expression occurs in approximately 10-20% of gastric cancers. While HER2-positive tumors tend to behave more aggressively, anti-HER2 therapy has markedly improved outcomes in this subgroup. Trastuzumab (Tmab) and trastuzumab deruxtecan (T-DXd) are key agents, yet real-world data on how these treatments are delivered and tolerated remain scarce. PATIENTS AND METHODS: We retrospectively reviewed 43 patients with advanced or recurrent HER2-positive gastric or gastroesophageal junction cancer who received chemotherapy between 2014 and 2025. Clinical features, laboratory data, and treatment courses were extracted from medical records. Overall survival (OS) was analyzed using Kaplan-Meier methods and prognostic factors using Cox regression. RESULTS: The median age was 70 years, and 81% of tumors were HER2 immunohistochemistry (IHC) 3+. Median OS was 29.6 months, with 3- and 5-year survival rates of 36% and 29%, respectively. Longer OS was linked with HER2 3+ status, gastrectomy, single metastatic site, normal lactate dehydrogenase (LDH), low neutrophil-to-lymphocyte ratio, and lower modified Glasgow Prognostic Score (mGPS). Patients maintaining anti-HER2 therapy ≥260 days lived significantly longer than those treated for a shorter duration (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsErb-b2 Receptor Tyrosine KinasesTrastuzumabNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansFemaleAgedPrognosisRetrospective StudiesMaleMiddle AgedAged, 80 and overCamptothecinImmunoconjugates

Stichwörter der Autor:innen

HER2-positive gastric canceranti-HER2 therapytrastuzumabtrastuzumab deruxtecan

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humantrastuzumab deruxtecanCamptothecinAntineoplastic Agents, ImmunologicalImmunoconjugates

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, Osaka, Japan.
  • Department of Gastroenterological Surgery, The University of Osaka Graduate School of Medicine, Osaka, Japan taroh@cfs.med.osaka-u.ac.jp.

Zitieren

APA

Wada, N., Kurokawa, Y., Takahashi, T., Saito, T., Hagi, T., Nakai, S., Momose, K., Yamashita, K., Tanaka, K., Makino, T., Eguchi, H., Doki, Y., & Satoh, T. (2026). Treatment Patterns and Prognostic Factors of Anti-HER2 Therapy in HER2-positive Advanced/Recurrent Gastric Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.18001

Vancouver

Wada N, Kurokawa Y, Takahashi T, Saito T, Hagi T, Nakai S, et al. Treatment Patterns and Prognostic Factors of Anti-HER2 Therapy in HER2-positive Advanced/Recurrent Gastric Cancer. Anticancer Research. 2026. doi:10.21873/anticanres.18001

BibTeX
@article{Wada2026,
  author = {Wada, Noriko and Kurokawa, Yukinori and Takahashi, Tsuyoshi and Saito, Takuro and Hagi, Takaomi and Nakai, Shigeto and Momose, Kota and Yamashita, Kotaro and Tanaka, Koji and Makino, Tomoki and Eguchi, Hidetoshi and Doki, Yuichiro and Satoh, Taroh},
  title = {Treatment Patterns and Prognostic Factors of Anti-HER2 Therapy in HER2-positive Advanced/Recurrent Gastric Cancer},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18001}
}
Kostenlos starten →